問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


Taipei Medical University-Shuang Ho Hospital,Ministry of Health and Welfare (在職)

Division of Psychiatry

Division of Psychiatry

Taipei Medical University Hospital (在職)

Division of Psychiatry

Division of Psychiatry

更新時間：2023-09-19

李信謙 LEE, HSIN-CHIEN
  • Principal Investigator
  • Clinical Trial Experience (year) -18 years -3 個月

Recruiting Trial

10Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

李信謙

List

25Cases

2026-05-05 - 2029-01-08

Phase III

Active
Efficacy and safety of NNC0487-0111 s.c. once-weekly in participants with overweight or obesity, and obstructive sleep apnoea treated with positive airway pressure (AMAZE 4)

  • Condition/Disease

    Obesity, Obstructive Sleep Apnoea

  • Test Drug

    NNC0487-0111 B

Participate Sites
4Sites

Not yet recruiting4Sites

2026-05-05 - 2029-02-21

Phase III

Not yet recruiting
Efficacy and safety of NNC0487-0111 s.c. once-weekly in participants with overweight or obesity, and obstructive sleep apnoea not treated with positive airway pressure (AMAZE 3)

  • Condition/Disease

    Obesity, Obstructive Sleep Apnoea

  • Test Drug

    NNC0487-0111 B

Participate Sites
4Sites

Not yet recruiting4Sites

2026-07-01 - 2029-05-31

Phase III

Active
A Randomized, Double-blind, Multicenter, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Esketamine Nasal Spray, Administered as Monotherapy, in Adult Participants With Treatment-resistant Depression

  • Condition/Disease

    Depressive Disorder, Treatment-Resistant

  • Test Drug

    鼻用噴液劑 鼻用噴液劑

Participate Sites
6Sites

Not yet recruiting4Sites

Recruiting2Sites

2017-02-01 - 2022-12-20

Phase III

Completed
An Open-label Long-term Extension Safety Study of Esketamine Nasal Spray in Treatment-resistant Depression

  • Condition/Disease

    Depressive Disorder, Treatment-Resistant

  • Test Drug

    ESKETAMINE

Participate Sites
6Sites

Terminated5Sites

Study ended1Sites

李信謙
Taipei Medical University-Shuang Ho Hospital,Ministry of Health and Welfare

Division of Psychiatry

劉嘉逸
Linkou Chang Gung Medical Foundation

2026-06-15 - 2028-08-10

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Not yet recruiting4Sites

2020-10-15 - 2022-06-07

Phase III

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
10Sites

Recruiting10Sites

2021-04-26 - 2024-07-22

Phase III

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Not yet recruiting2Sites

Recruiting4Sites

2022-10-01 - 2026-02-24

Phase IV

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
1Sites

Recruiting1Sites

2024-10-01 - 2026-12-31

Phase I

Active

  • Condition/Disease

  • Test Drug

Participate Sites
1Sites

Recruiting1Sites

2023-04-01 - 2026-01-31

Phase III

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Recruiting4Sites

1 2 3
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB